Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.
- This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's.
- This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau.
- The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
- The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics.